Indication for the potential treatment of various leukemias, including chronic myeloid leukemia (cml).pharmacodynamics nilotinib is a transduction inhibitor that targets bcr-abl, c-kit and pdgf, for the potential treatment of various leukemias, including chronic myeloid leukemia (cml).mechanism of action chronic myelogenous leukaemia (cml) is caused by the bcr-abl oncogene. nilotinib inhibits the tyrosine kinase activity of the bcr-abl protein. nilotinib fits into the atp-binding site of the bcr-abl protein with higher affinity than imatinib, over-riding resistance caused by mutations. the ability of amn107 to inhibit tel-platelet-derived growth factor receptor-beta (tel-pdgfrbeta), which causes chronic myelomonocytic leukaemia, and fip1-like-1-pdgfralpha, which causes hypereosinophilic syndrome, suggests potential use of amn107 for myeloproliferative diseases characterised by these kinase fusions (stover et al, 2005- weisberg et al, 2005). amn107 also inhibits the c-kit receptor k
Voir plus de détails